Cavinton, Ampoules 50mg, 10ml, 5pcs

Composition

>

1 ml contains vinpocetine 5 mg. 1 amp. – 50 mg.

Auxiliary substances:

ascorbic acid,

sodium disulfite,

tartaric acid,

benzyl alcohol,

sorbitol,

d/i water.

Pharmacological action

Cavinton is a drug that improves cerebral circulation, brain metabolism and rheological properties of blood. It has a cerebroprotective effect. Reduces the severity of damaging cytotoxic reactions caused by stimulating amino acids; inhibits the functional activity of both cellular transmembrane sodium and calcium channels, and NMDA and AMPA receptors. Potentiates the neuroprotective effect of adenosine.

It stimulates brain metabolism, increases the absorption and assimilation of glucose and oxygen by the brain. It stimulates glucose transport through the BBB, shifts glucose metabolism to an energetically more favorable aerobic direction. Selectively inhibits Ca2+ – calmodulin-dependent cGMP phosphodiesterase, increases the concentration of cAMP and cGMP in brain tissues, as well as the concentration of ATP and the ratio of ATP/AMP. It stimulates the cerebral metabolism of norepinephrine and serotonin, stimulates the ascending noradrenergic system, and has an antioxidant effect.

The drug selectively enhances cerebral blood flow: increases the brain fraction of the minute volume; reduces the resistance of brain vessels, without affecting the parameters of general blood circulation (blood pressure, minute volume, heart rate, OPSS).

It does not cause the phenomenon of “robbing”; on the contrary, when it is used, first of all, the blood supply to the ischemic, but still viable area with low perfusion increases – the phenomenon of “reverse robbing”.

Improves the tolerance of hypoxia by brain cells, promoting the transport of oxygen to tissues due to a decrease in the affinity of red blood cells for it.

The drug improves the microcirculation of the brain, inhibits platelet aggregation, reduces pathologically increased blood viscosity, increases the deformability of red blood cells and blocks their absorption of adenosine.

Indications

In neurology – acute and chronic cerebrovascular insufficiency (transient ischemia, progressive stroke, post-stroke conditions, vascular dementia, cerebral vascular atherosclerosis, post-traumatic and hypertensive encephalopathy, vertebrobasilar insufficiency); mental and neurological disorders in patients with cerebrovascular insufficiency (including memory impairment, dizziness, headache, aphasia, apraxia, movement disorders).

In ophthalmology-vascular diseases of the eyes (atherosclerosis, angiospasm of the choroid and retina, degenerative diseases of the choroid, retina or macula, arterial and venous thrombosis or embolism, secondary glaucoma).

In ENT practice-hearing loss (vascular, toxic or age-related), Meniere’s disease, cochleovestibular neuritis, tinnitus, dizziness (labyrinth origin); vasovegetative manifestations of menopausal syndrome.

Use during pregnancy and lactation

The drug is contraindicated during pregnancy and lactation.

Contraindications

• Acute phase of hemorrhagic stroke;
• Severe CHD;
• Severe arrhythmias.
• Under 18 years of age (due to insufficient data).
• Known hypersensitivity to vinpocetine.

Side effects

From the cardiovascular system:  it is possible to increase the manifestations of existing arrhythmia.

From the digestive system:  nausea, heartburn, dry mouth.

From the central nervous system:  headache, dizziness, sleep disturbance, weakness.

Allergic reactions:  skin rash, urticaria.

Skin reactions:  hyperemia of the skin.

How to take, course of use and dosage

The drug is intended for intravenous drip infusion. Enter slowly, the infusion rate should not exceed 80 drops/min. It is

forbidden to enter IV and IV without dilution.

To prepare the infusion, you can use saline or dextrose-containing solutions (Salsol, Ringer, Rindex, Reomacrodex). Infusion solution with Cavinton should be used in the first 3 hours after preparation.

The usual initial daily dose is 20-25 mg in 500 ml of infusion solution. Depending on the tolerance, the dose can be increased to no more than 1 mg/kg/day within 2-3 days. The average duration of treatment is 10-14 days.

The average daily dose for a body weight of 70 kg is 50 mg (in 500 ml of infusion solution).

No dose adjustment is required for liver and kidney diseases.

At the end of the IV therapy course, it is recommended to continue treatment with Cavinton Forte tablets (1 tab. 3 times/day). or Cavinton (2 tablets 3 times/day).

Overdose

Currently, data on overdose of Cavinton are limited.

Treatment: performing symptomatic therapy.

Special instructions

Cavinton does not have a hepatotoxic and nephrotoxic effect, so when prescribing the drug to patients with liver and kidney diseases, no dosage adjustment is required. Use in pediatrics, it is recommended to prescribe the drug to children under the age of 18 years due to the lack of experience in using Cavinton in this category of patients.

Form of production

The solution for infusions is concentrated.

Storage conditions

In a dark place, at a temperature of 15-30 °C

Shelf life

5 years

Active ingredient

Vinpocetine

Conditions of release from pharmacies

By prescription

Dosage form

infusion solution